Related Experiment Video
Updated: Jun 15, 2026
09:29
Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
Neuromyelitis optica: an overview
R Nandhagopal1, Abdullah Al-Asmi, Arunodaya R Gujjar
1Neurology Unit, Department of Medicine, College of Medicine & Health Sciences, Sultan Qaboos University Hospital, Al Khod, Oman. rnandagopal@yahoo.com
Postgraduate Medical Journal
|March 19, 2010
Summary
Neuromyelitis optica (NMO) is an autoimmune disorder affecting the central nervous system. Early diagnosis and long-term immunosuppression are crucial for managing NMO and preventing relapses.
Area of Science:
- Neuroimmunology
- Autoimmune Disorders
- Central Nervous System Inflammation
Background:
- Neuromyelitis optica (NMO) is a relapsing inflammatory condition of the central nervous system, often mistaken for multiple sclerosis.
- Recent understanding has expanded the clinical spectrum of NMO, including limited forms and associations with other autoimmune diseases.
- Cerebral lesions may be present in NMO and do not exclude the diagnosis.
Purpose of the Study:
- To review current knowledge on neuromyelitis optica (NMO).
- To discuss epidemiology, clinical presentation, immunopathology, diagnosis, and management of NMO.
- To differentiate NMO from multiple sclerosis.
Main Methods:
- Review of recent literature on neuromyelitis optica.
- Analysis of clinical, radiological, and laboratory findings.
- Discussion of immunopathology, particularly the role of aquaporin 4 antibodies.
Main Results:
- Aquaporin 4 antibody is a key pathogenetic factor and diagnostic marker for NMO, classifying it as an autoimmune channelopathy.
- Longitudinally extensive myelitis on spinal MRI supports the diagnosis in the appropriate clinical context.
- NMO differs from multiple sclerosis based on clinical, radiological, and laboratory data.
Conclusions:
- NMO requires distinct diagnostic and management strategies compared to multiple sclerosis.
- Relapse prevention through long-term immunosuppressive therapy is the primary goal in managing NMO.
- Understanding the immunopathology, including the role of aquaporin 4 antibodies, is vital for effective NMO treatment.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:26Encephalitis ll: Pathophysiology
Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...